MedTrace Logo

"As Required" Oral Sildenafil in Raynaud's Phenomenon

NCT02050360 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2016-01-18

No results posted yet for this study

Summary

The purpose of this study is to determine whether "on-demand" sildenafil is effective in the treatment of Raynaud's phenomenon.

Conditions

  • Raynaud's Phenomenon

Interventions

DRUG

Sildenafil 40 mg

DRUG

Sildenafil 80 mg

DRUG

Placebo

Sponsors & Collaborators

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Jean-Luc CRACOWSKI, MD · INSERM CIC03 - Unité de Pharmacologie Clinique

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02050360 on ClinicalTrials.gov